Back to Search
Start Over
The potential of patient-derived organoids in precision medicine of biliary tract cancer.
- Source :
-
Cell reports. Medicine [Cell Rep Med] 2023 Nov 21; Vol. 4 (11), pp. 101294. - Publication Year :
- 2023
-
Abstract
- Chemotherapy resistance in biliary tract cancer (BTC) presents a major clinical hurdle. Ren et al. <superscript>1</superscript> developed and characterized an extensive collection of BTC patient-derived organoid (PDO) models, enabling advanced investigation of chemotherapy response prediction.<br />Competing Interests: Declaration of interests T.M. reports scientific consultancy role for Ability Pharmaceuticals SL, AstraZeneca, Basilea Pharma, Baxter, BioLineRX Ltd, Celgene, Eisai, Incyte, Ipsen Bioscience Inc, speaker’s fee for Janssen and Lilly, and research funding for MSD, Novocure, QED Therapeutics, Roche Farma, Sanofi-Aventis, Servier, and Zymeworks. T.V.T. reports grants from Loxo Oncology at Lilly, Pharmaxis, Alentis, Incyte, and nonfinancial support from Servier.<br /> (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 2666-3791
- Volume :
- 4
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Cell reports. Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 37992681
- Full Text :
- https://doi.org/10.1016/j.xcrm.2023.101294